Evaluation of the Safety, Tolerability and Efficacy of Ezetimibe on a Select Population of Filipinos With Hypercholesterolemia (Study P04748)(COMPLETED)

Safety as Measured by Number of Subjects With at Least One Adverse Event

Evaluation of the overall safety of ezetimibe as measured by number of subjects who experienced at least one adverse event

Time frame: 28 days after Visit 1

Safety as Measured by Number and Type of Adverse Events.

Evaluation of the overall safety of ezetimibe as measured by the number and type of adverse events.

Time frame: 28 days after Visit 1

Safety as Measured by Severity of Adverse Events as Determined by the Investigator

To evaulate the safety of ezetimibe as measured by severity of adverse events, as determined by the investigator

Time frame: 28 days after Visit 1

Safety as Measured by Adverse Event Relatedness to Study Drug as Reported by the Investigator.

To evaluate the overall safety of ezetimibe as measured by adverse event relatedness to study drug as reported by the investigator.

Time frame: 28 days after Visit 1

Safety as Measured by Dose Adjustment Upon Incidence of an Adverse Event

To evaluate the overall safety of ezetimibe as measured by action taken by the investigator upon incidence of an adverse event

Time frame: 28 days after Visit 1

Safety as Measured by Outcome of Adverse Events

To evaluate overall safety of ezetimibe as measured by outcome of adverse events

Time frame: 28 days after Visit 1

Tolerability as Measured by Subject Self-assessment

Evaluation of the overall tolerability of ezetimibe as measured by subject self-assessment

Time frame: 28 days after Visit 1